Send us a Message

In this first MedTech 101 episode of the year, Rodney Moses explores where MedTech is heading in 2026 and beyond. Drawing from industry history, market data, and real-world regulatory experience, he identifies three key growth pillars shaping the future of healthcare: telemedicine, artificial intelligence, and personalised medicine.

Using Intuitive Surgical as a case study, Rodney explains how patents, monopolies, and regulation influence innovation and market expansion. He then breaks down why telemedicine is accelerating rapidly, how AI is enhancing (not replacing) clinicians, and why personalised medicine is set to become a trillion-dollar market.

This episode offers a clear investment, innovation, and career lens on where MedTech is moving—and where attention should be focused over the next five years.

⏱️ Episode Time-Step Summary (Chapters)

(0:00–0:20) High-Growth MedTech Thesis
MedTech companies operating in telemedicine, AI, and personalised medicine are positioned for strong long-term growth.

(0:20–1:55) Welcome & Podcast Update
Rodney Moses welcomes listeners to the first episode of the year, reflects on fewer episodes in 2025, and shares updates on starting postgraduate studies in Munich and expanding the podcast’s scope.

(1:55–2:23) Framing the Future of MedTech
To predict the future of MedTech, we must first understand the present and recent history of the industry.

(2:23–4:08) Intuitive Surgical & Market Evolution
Intuitive Surgical’s early patents created a long-lasting monopoly in surgical robotics. Patent expiry enabled competitors, lowered regulatory barriers, and expanded the market.

(4:08–4:59) Innovation, Patents & Regulation
Discussion on balancing patent protection, innovation incentives, affordability, and the role of regulation in MedTech markets.

(4:59–6:35) Telemedicine: Market Growth & Impact
Telemedicine as a key future pillar of MedTech, driven by wearables and remote monitoring.

• Market size: $141B (2024) → $380B (2030)
• Benefits include hospital decongestion and improved access to care.

(6:35–10:00) Artificial Intelligence in MedTech
AI as an enabler rather than a replacement for doctors. Use cases include diagnostics, imaging, mental health analysis, and decision support.

• Market size: $14B (2024) → $255B (2033)
  Regulatory catch-up remains a challenge, but momentum is strong.

(10:06–11:22) Personalised Medicine & Data-Driven Care
Shift from generalized treatments to tailored therapies based on individual patient data, improving efficacy and outcomes.

(11:22–11:54) Personalised Medicine Market Outlook
One of the fastest-growing healthcare markets globally.

• Market size: $567B (2024) → $1.2T (2033)

(11:54–12:57) Where to Focus in MedTech
The three strongest growth areas for the next 1–5 years:

1. Telemedicine
2. Artificial Intelligence
3. Personalised Medicine
   Surgical robotics remains important but secondary in near-term growth.

(12:57–13:11) Closing Remarks
Rodney thanks listeners, marks his return to the podcast, and invites guest and topic suggesti

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

In this compelling episode of MedTech 101, host Rodney Moses sits down with RenovoRx CEO Shaun Bagai to explore the latest breakthroughs in cancer treatment. The conversation opens with a clear-eyed look at the challenges pancreatic cancer patients face, before diving into Shaun’s remarkable journey—from aspiring pre-med student to seasoned medtech leader—and the pivotal role engineering plays in redefining cancer care.

Rodney underscores the importance of pairing technological innovation with true patient-centric thinking, setting the tone for an insightful discussion on medtech’s ability to transform lives.

Shaun explains how RenovoRx is changing the treatment landscape through its patented localized therapy platform, designed to deliver chemotherapy directly to the tumor while reducing life-limiting systemic side effects. Their discussion highlights the development and impact of the RenovoCath catheter and the Trans-Arterial Micro-Perfusion (TAMP) system, technologies that enable precise, targeted drug delivery and bring renewed hope for improved outcomes.

Rodney and Shaun also touch on the contrast between the agility of startups and the slower pace of traditional medtech companies—using RenovoRx’s journey to a NASDAQ listing, without being acquired by a larger player, as a powerful example of strategic independence. The episode wraps with optimism about the future of oncology and the transformative potential of smarter drug-delivery systems.

Timestamp Summary

00:00 | Innovative Approach to Treating Pancreatic Cancer Locally
01:50 | Renovo Rx's Innovative Approach to Localized Chemotherapy Delivery
02:31 | From Medtronic to CEO: A Journey in Medical Innovation
05:28 | Leveraging Technology in Medicine for Widespread Impact
06:47 | RenovoRx's Unique Path in the Medtech Industry
12:39 | Innovative Localized Chemotherapy for Pancreatic Cancer Treatment
19:22 | Expanding Life-Saving Technology Beyond the US Market
21:02 | Innovative Delivery Systems for Pancreatic Cancer Treatment

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

Viral Thakkar, COO of LungPacer Medical, joins Rodney on the MedTech 101 Podcast to discuss how cutting-edge innovation is reshaping ventilator technology. They unpack the limitations of traditional mechanical ventilation and its often-overlooked effects on the diaphragm. Viral shares insights into AeroPace, LungPacer’s breakthrough system that uses phrenic nerve stimulation to help patients breathe and recover more effectively.

The discussion dives into the real-world challenges of clinical adoption, the significance of FDA Breakthrough Designation, and what the future holds for ventilation care. Tune in to learn how this technology could redefine outcomes for ICU patients by reducing complications and accelerating recovery.

Timestamp
00:00 The Impact of Mechanical Ventilation on Diaphragm Health
02:02 From R&D to COO: Viral Thakkar's Medtech Journey
03:20 A Journey from Personal Tragedy to Medical Device Innovation
05:56 Ventilator-Induced Diaphragm Dysfunction and Its Consequences
11:38 Innovative Diaphragm Stimulation Technology for Improved Ventilation
15:45 Breakthrough Medical Device Designation and Market Challenges
19:27 Innovative Ventilation Technology Aims to Improve ICU Patient Outcomes

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

Ben Tasker, is an AI expert who has transitioned from academia to the utilities sector, focusing on upskilling and reskilling the workforce for the AI era. He discusses his experience developing AI systems for student success prediction in education and cancer risk identification in healthcare.

The core themes are:

The importance of responsible and ethical AI practices as the technology rapidly advances
The challenges of getting buy-in from end-users (students, patients, employees) and integrating AI into existing workflows
The potential of AI to enable more personalized services, especially in healthcare and mental health
The need to balance the benefits of AI-powered personalization with concerns around privacy, transparency, and the risk of reinforcing biases

Overall, Ben emphasizes the critical role of human-centered design and stakeholder engagement in ensuring AI is implemented effectively and ethically across different industries.

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

Dr Kevin Tracey is a renowned neurosurgeon and the president of the Feinstein Institutes for Medical Research. With over three decades of experience focused on understanding and controlling inflammation. Dr Tracey has pioneered research that led to advancements in bioelectronic medicine. His work explores the potential of the vagus nerve to regulate inflammation, paving the way for innovative treatments for chronic conditions like rheumatoid arthritis. Kevin is also a co-founder of SetPoint Medical, which recently received FDA approval for an implant device aimed at treating inflammation.

Timestamp

00:00 Bioelectronic Devices Revolutionize Inflammation Treatment
04:28 Exploring Bioelectronic Medicine and Innovative Medical Research
09:09 Vagus Nerve Stimulation as a Breakthrough in Inflammation Treatment
13:07 Implant Revolutionizes Rheumatoid Arthritis Treatment
15:56 Vagus Nerve Stimulation and Its Role in Inflammation Control
20:25 SetPoint Medical's FDA Approval and Future Distribution Challenges
24:08 The Promise of Vagus Nerve Stimulation for Rheumatoid Arthritis
27:29 Understanding Present Data to Predict Future Technological Advancements
29:48 Vagus Nerve Stimulation as a Future Inflammation Treatment
32:16 Podcast Interview with Author Kevin Tracey

Book: The Great Nerve: The New Science of the Vagus Nerve and How to Harness Its Healing Reflexes

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

In this episode of the MedTech 101 podcast, host Rodney Moses sits down with Erin Lee, CEO of Flow Neuroscience, to talk about how technology is changing the way we treat mental health.

Erin shares the story behind Flow’s groundbreaking device that uses gentle brain stimulation to treat depression, without relying on traditional antidepressants. Together, they discuss the challenges of drug-based therapies and Flow’s mission to make mental health treatment more effective, affordable, and accessible.

Erin also opens up about her unconventional journey into medtech, from her time at leading tech firms to her eye-opening experience at Babylon Health, which shaped her vision for digital health innovation.

The conversation dives into how Flow operates as a Scandinavian company with a global footprint, spanning the UK, EU, and now expanding into the U.S. market. Erin explains the regulatory hurdles they face, how they navigate them, and what it takes to bring such a device to different regions.

She also talks about Flow’s wearable headset — a clinically proven, non-drug treatment that uses targeted electrical stimulation to improve mood. Finally, Erin reflects on the future of mental health care, where AI and medtech could work together to deliver more personalized and accessible treatments for people everywhere.

Timestamp

00:00 Revolutionizing Depression Treatment Without Antidepressants
01:44 Erin Lee's Unconventional Journey to Leading Flow Neuroscience
06:07 Innovative Headset Offers Drug-Free Depression Treatment
12:17 Challenges and Strategies in Medical Device Market Approvals
15:53 Challenges in Introducing Innovative Medical Devices to the Market
22:41 The Future of Personalized Brain Stimulation for Depression Treatment
29:31 Erin Lee Discusses Neuroscience and Upcoming Device Launch

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

In this episode, Rodney sits down with Henry O’Connell, co-founder of Canary Speech, to explore how vocal biomarkers are changing the way we understand health. From detecting anxiety and depression to assessing cognitive function, Canary Speech’s approach breaks through language barriers and gives clinicians clearer insights into patient care. Together, Rodney and Henry discuss how this innovation could open the door to more accessible healthcare—from Utah to the most remote corners of the world.

Timestamp

00:00 Canary Speech and the Future of Vocal Biomarkers
07:23 Understanding Emotional Cues in Family Interactions
10:16 Revolutionizing Healthcare with Ambient Listening and AI Analysis
22:54 Understanding Vocal Cords and Emotional Speech Patterns
25:31 AI Revolutionizing Mental Health Diagnosis and Treatment
33:09 Leveraging Technology to Equalize Global Healthcare Access
38:31 Connecting with Henry O'Connell Through LinkedIn and Email

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal

Send us a Message

In this enlightening episode of the MedTech 101 podcast, host Rodney introduces the unique and transformative work of Sinan Golhan, CEO of Geltech, who is at the forefront of advancing hydrogel technology. Hydrogels have the extraordinary capacity to absorb up to 10,000 times their weight in water, making them invaluable across diverse fields such as medtech, pharmaceuticals, and even cosmetics. This episode unravels how Geltech is making significant strides in streamlining hydrogel research through automation, reducing the cost of testing and accelerating the timeline for hydrogel innovations to benefit various industries.

As the discussion progresses, Sinan shares his personal journey from UC San Diego to founding Geltech. Motivated by a poignant family health challenge, Sinan's quest has been to enhance the precision of cancer treatments via hydrogels. Throughout this conversation, Sinan delves deep into the hurdles of fundraising and the scalable solutions devised by Geltech to expedite and automate the labor-intensive process of hydrogel testing. Listeners gain an insight into the potential future

Timestamp

00:00 Innovative Hydrogel Applications in MedTech and Pharmaceuticals
03:14 Innovating Cancer Treatment Through Robotics and Personal Motivation
05:29 Hydrogels: Transformative Applications in Medicine and Biotechnology
08:28 Revolutionizing Hydrogel Testing with Automated Lab Technology
15:45 Challenges and Strategies in Raising Capital for Startups
17:30 Unexpected Networking Leads to Successful Startup Fundraising
23:17 The Future of 3D-Printed Hydrogels in MedTech


GelTech https://www.geltechlabs.com

Support the show

Follow or Connect with Rodney Moses:
Instagram | LinkedIn | YouTube |

Donations
Patreon | PayPal